Florence Oluwatoyin Akintepede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Florence Oluwatoyin Akintepede has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
2 shared publications - Gbolahan Olatunji
Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria
2 shared publications - Israel Charles Abraham
University of Ilorin, Ilorin, Nigeria
2 shared publications - Nicholas Aderinto
Ladoke Akintola University of Technology, Ogbomosho, Nigeria
2 shared publications - Sulaiman Olaide Bukky
Accident and Emergency, Mid Cheshire NHS Trust, Cheshire, UK
2 shared publications - Abieyuwa Tari-Ere Oshodin
Department of Medicine and Surgery, Obafemi Awolowo University Teaching Hospital, Ife, Nigeria
1 shared publication
Latest Publications
- Open Access
- 27 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 569-579
Efficacy and safety of dual-task training in enhancing cognitive and motor recovery for post-stroke rehabilitation
Stroke is a leading cause of disability and mortality worldwide, with survivors frequently experiencing motor and cognitive impairments that hinder their daily functioning and independence. Dual-task training (DTT), an innovative rehabilitation approach, targets simultaneous improvement in motor and cognitive functions by addressing cognitive-motor interference. This narrative review evaluates the efficacy and safety of DTT in poststroke rehabilitation. PubMed, Google Scholar, Cochrane Library, Scopus, and the Directory of Open Access Journals were searched, yielding 31 studies, including randomized controlled trials and observational studies. Articles were identified that evaluated the safety and efficacy of DTT for poststroke rehabilitation in patients who had suffered from hemorrhagic or ischemic stroke. Before extracting variables, the studies were imported into Rayyan software, and thematic analysis was subsequently conducted using Microsoft Excel. The findings indicate that DTT enhances gait parameters, balance, and cognitive functions, particularly attention and executive function. Additionally, it improves functional outcomes, including activities of daily living, and reduces fall risk. While DTT demonstrates promise in fostering neuroplasticity and improving recovery outcomes, questions regarding its long-term efficacy, optimal implementation, and safety warrant further investigation. This review highlights the potential of DTT as a promising approach in stroke rehabilitation, supporting more integrated recovery strategies.
- 27 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 569-579
Open AccessEfficacy and safety of dual-task training in enhancing cognitive and motor recovery for post-stroke rehabilitation
Stroke is a leading cause of disability and mortality worldwide, with survivors frequently experiencing motor and cognitive impairments that hinder their daily functioning and independence. Dual-task training (DTT), an innovative rehabilitation approach, targets simultaneous improvement in motor and cognitive functions by addressing cognitive-motor interference. This narrative review evaluates the efficacy and safety of DTT in poststroke rehabilitation. PubMed, Google Scholar, Cochrane Library, Scopus, and the Directory of Open Access Journals were searched, yielding 31 studies, including randomized controlled trials and observational studies. Articles were identified that evaluated the safety and efficacy of DTT for poststroke rehabilitation in patients who had suffered from hemorrhagic or ischemic stroke. Before extracting variables, the studies were imported into Rayyan software, and thematic analysis was subsequently conducted using Microsoft Excel. The findings indicate that DTT enhances gait parameters, balance, and cognitive functions, particularly attention and executive function. Additionally, it improves functional outcomes, including activities of daily living, and reduces fall risk. While DTT demonstrates promise in fostering neuroplasticity and improving recovery outcomes, questions regarding its long-term efficacy, optimal implementation, and safety warrant further investigation. This review highlights the potential of DTT as a promising approach in stroke rehabilitation, supporting more integrated recovery strategies.
- Open Access
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8478-8485
Umbrella review of anticoagulation strategies for secondary prevention of cardioembolic stroke in atrial fibrillation: efficacy, safety, and knowledge gaps
Atrial fibrillation (AF) is a major contributor to cardioembolic stroke. Anticoagulation, guided by CHA2DS2-VASc and HAS-BLED scores, is critical for secondary prevention, yet challenges persist in timing, patient-specific tailoring, and balancing efficacy with bleeding risk. This umbrella review synthesizes evidence on anticoagulation strategies for secondary prevention of cardioembolic stroke in AF patients. We searched PubMed, Scopus, Cochrane Library, Web of Science, and Embase for systematic reviews and meta-analyses (inception to May 2025) assessing oral anticoagulants (OACs) [vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs)] in AF patients with prior stroke or transient ischemic attack (TIA). Outcomes included recurrent stroke, systemic embolism, major bleeding, intracranial hemorrhage (ICH), and mortality. Quality was assessed using AMSTAR-2. Data were narratively synthesized, with quantitative metrics extracted where feasible. Eight reviews (2007–2025) were included, comprising 4–52 studies and 6893–94 656 participants. DOACs demonstrated superior efficacy over VKAs [apixaban odds ratio (OR) 0.79, 95% confidence interval (CI) 0.66–0.94], and VKAs outperformed antiplatelets (relative risk reduction 64%, absolute risk reduction 8.4%/year). DOACs showed lower major bleeding and ICH rates than VKAs, with apixaban exhibiting the most favorable safety profile (OR 0.71, 95% CI 0.61–0.81). Early versus delayed OAC initiation post-stroke improved efficacy (OR 0.68, 95% CI 0.55–0.84) with comparable safety. Identified knowledge gaps include optimal timing of OACs, outcomes in high-risk subgroups (elderly, renal impairment, and post-ICH), and cost-effectiveness. DOACs are superior to VKAs for secondary prevention of cardioembolic stroke in AF. However, individualized approaches are needed for timing and high-risk subgroups.
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8478-8485
Open AccessUmbrella review of anticoagulation strategies for secondary prevention of cardioembolic stroke in atrial fibrillation: efficacy, safety, and knowledge gaps
Atrial fibrillation (AF) is a major contributor to cardioembolic stroke. Anticoagulation, guided by CHA2DS2-VASc and HAS-BLED scores, is critical for secondary prevention, yet challenges persist in timing, patient-specific tailoring, and balancing efficacy with bleeding risk. This umbrella review synthesizes evidence on anticoagulation strategies for secondary prevention of cardioembolic stroke in AF patients. We searched PubMed, Scopus, Cochrane Library, Web of Science, and Embase for systematic reviews and meta-analyses (inception to May 2025) assessing oral anticoagulants (OACs) [vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs)] in AF patients with prior stroke or transient ischemic attack (TIA). Outcomes included recurrent stroke, systemic embolism, major bleeding, intracranial hemorrhage (ICH), and mortality. Quality was assessed using AMSTAR-2. Data were narratively synthesized, with quantitative metrics extracted where feasible. Eight reviews (2007–2025) were included, comprising 4–52 studies and 6893–94 656 participants. DOACs demonstrated superior efficacy over VKAs [apixaban odds ratio (OR) 0.79, 95% confidence interval (CI) 0.66–0.94], and VKAs outperformed antiplatelets (relative risk reduction 64%, absolute risk reduction 8.4%/year). DOACs showed lower major bleeding and ICH rates than VKAs, with apixaban exhibiting the most favorable safety profile (OR 0.71, 95% CI 0.61–0.81). Early versus delayed OAC initiation post-stroke improved efficacy (OR 0.68, 95% CI 0.55–0.84) with comparable safety. Identified knowledge gaps include optimal timing of OACs, outcomes in high-risk subgroups (elderly, renal impairment, and post-ICH), and cost-effectiveness. DOACs are superior to VKAs for secondary prevention of cardioembolic stroke in AF. However, individualized approaches are needed for timing and high-risk subgroups.